SCHEMBL3639738

SCHEMBL3639738

FC(F)(F)c1ccc(-c2n[nH]cc2CNc2cccc(Oc3ccccn3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 3/20 0.43
GRK2 P25098 1/20 0.39
RHOA P61586 1/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 1/20 0.38
F2 P00734 1/20 0.38
BRD4 O60885 2/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK1 P28482 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
KDR P35968 1/20 0.37
CLK1 P49759 1/20 0.37
DYRK1A Q13627 1/20 0.37
PPARA Q07869 1/20 0.37
P2RY1 P47900 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636635 0.88 GRK2 (0.47) MAP2K7GRK2GAAMAPTF2
SCHEMBL3638627 0.83 MAPT (0.47) GRK2GAAMAPTL3MBTL1HDAC1
SCHEMBL3636746 0.83 HDAC1 (0.51) GRK2GAAMAPTKDM4EHDAC1
SCHEMBL3640361 0.83 FLT1 (0.40) GAAMAPTKDRCLK1DYRK1A
SCHEMBL27991324 0.82 MAPT (0.39) MAP2K7GRK2GAAMAPTCLK1
SCHEMBL3636214 0.81 MAPT (0.49) GAAMAPTBRD4KDM4EL3MBTL1
SCHEMBL3800645 0.80 GAA (0.40) GRK2GAAMAPTF2CLK1
SCHEMBL3635323 0.79 MAPT (0.40) MAP2K7GRK2GAAMAPTCLK1
SCHEMBL3638354 0.79 HDAC1 (0.47) GAAMAPTKDM4EL3MBTL1CLK1
SCHEMBL3636992 0.78 CACNA1B (0.44) MAPTBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MAP2K7 3136/4885GRK2 26/4885RHOA 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.